Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer

Journal:

The New England Journal of Medicine

Published:

2025-05-31

DOI:

10.1056/nejmoa2501912

Affiliations:

22

Authors:

20

Go to article

Institutions	Authors	Share
Pfizer, United States of America (USA)	3.000000	0.15
The University of Texas MD Anderson Cancer Center, United States of America (USA)	2.000000	0.10
Vall d'Hebron University Hospital (HUVH), ICS, Spain	1.666667	0.08
Vanderbilt University Medical Center (VUMC), United States of America (USA)	1.000000	0.05
University of Campania Luigi Vanvitelli, Italy	1.000000	0.05
Asan Medical Center (AMC), South Korea	1.000000	0.05
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)	1.000000	0.05
National Cancer Center Hospital East, Japan	1.000000	0.05
IRCCS Istituto Oncologico Veneto (IOV), Italy	1.000000	0.05
University of Liverpool, United Kingdom (UK)	1.000000	0.05
Hammersmith Hospital, Imperial College Healthcare NHS Trust, United Kingdom (UK)	1.000000	0.05
Mayo Clinic Hospital - Phoenix, United States of America (USA)	1.000000	0.05
Pfizer Italia srl, Italy	1.000000	0.05
Beijing Cancer Hospital / School of Oncology, PKUHSC, China	1.000000	0.05
Peter MacCallum Cancer Centre (Peter Mac), Australia	0.500000	0.03
University Hospitals Leuven (UZ Leuven), Belgium	0.500000	0.03
The University of Melbourne (UniMelb), Australia	0.500000	0.03
Catholic University of Leuven (KU Leuven), Belgium	0.500000	0.03
University of Vic - Central University of Catalonia (UVic-UCC), Spain	0.333333	0.02

Interested in Oncology and Carcinogenesis?